Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.
Revenue context before the current result.
Operating cash flow across covered periods.
Statutory profit after tax across covered periods.
Operating cash flow less capex before leases.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not available for this company right now.
EPS
Not available
Not available for this company right now.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
1.74x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY23 vs HY22
Revenue
$0.25m
-29.4% ↓ vs $0.36m
Net profit after tax
$0.7m
+128.0% ↑ vs −$2.5m
Net cash inflow from operating activities
−$3.7m
+1.7% ↑ vs −$3.7m
Operating profit
$0.63m
+116.2% ↑ vs −$3.9m
Profit before tax
$0.7m
+120.0% ↑ vs −$3.5m
Cash and cash equivalents
$1.7m
-24.5% ↓ vs $2.3m
Total assets
$29.1m
+3.8% ↑ vs $28m
What changed
With half-year operating outflows at roughly twice the closing cash position, runway is the dominant issue in this release.
Against that backdrop, reported earnings swung sharply: NPAT moved to +$0.719m from -$2.465m (+129.2%) and PBT moved to +$0.719m from -$3.478m (+120.7%). Management's own commentary references "excluding fair [value]" gains, indicating non-cash items drove the swing. Revenue fell 29.4% to $0.254m on a sub-million base. The company also ceased manufacturing during the period and signalled an imminent German launch.
What matters
Cash of $1.708m against half-year operating cash outflow of $3.664m implies less than six months of cover at the current burn rate before any further capital raise, working-capital release, or revenue ramp. Capex dropped to -$0.047m from -$0.311m (-84.9%), consistent with the decision to exit manufacturing, but it does not close the operating gap.
Reported profit does not reflect operating economics. FCF-to-NPAT of -516.4% versus +163.9% in HY22 confirms that the profit print is non-cash in nature. PBT growth of 120.7% is the cleaner accounting read, but even that overstates the underlying trajectory because operating cash outflows of $3.7m are largely unchanged year-on-year. The "fair value" reference in management's commentary is the disclosed driver investors need to size.
Strategy has pivoted before commercial revenue has arrived. Revenue fell 29.4% on a base that was already small, and the company is now reliant on third-party manufacturing plus European market entry (Germany launch-ready, Poland positioning) to generate the revenue scale needed to narrow the cash burn. This matters because the equity story has shifted from domestic build-out to export execution while operating losses continue.
Expectations
Management describes German launch as "imminent" and first revenues as "tantalisingly close," but neither timing nor sizing is disclosed. Prior-year shape data is not reliable enough to anchor a second-half expectation, so the release on its own supports only a qualitative read: H2 needs to deliver visible export revenue and a step-down in burn, otherwise capital adequacy becomes the binding constraint.
The gap between the qualitative tone of the commentary ("results as expected," "well-positioned") and the cash-balance trajectory is the central tension going into the second half.
Quality of result
Operating cash outflow of -$3.664m is essentially flat to -$3.728m a year earlier, while NPAT moved by +$3.184m. That divergence is reconciled by management's reference to fair-value gains rather than by improved trading. The headline tax-rate optics (0.0% current versus 29.1% prior) are also a function of the swing to profit on a non-cash item rather than an underlying tax outcome, so they should not be read as a recurring earnings lift.
Operating working-capital movement is immaterial at the group level, so the cash position is being depleted by operating losses rather than by inventory or receivables build. Inventories rose 64.3% to $0.138m but remain small in absolute terms. Total equity of $26.7m is roughly flat year-on-year, so the balance sheet is not yet flagging an impairment cycle, but ROE of 2.7% on a non-cash-driven profit overstates the economic return on that equity base.
Unresolved
This briefing cannot assess the size or recurrence of the fair-value gain, the exact runway, or the credibility of the European launch timeline because the release does not quantify those items.
Chat
Ask follow-up questions about Rua Bioscience's HY23 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
company filing
HY23 / results announcementInterim Financial Statements 31 December 2022
HY23 / financial reportInterim Financial Statements Market Announcement
HY23 / results releaseResults Announcement
HY22 / results announcementRua Bioscience Interim Financial Statements Market Announcement
HY22 / results releaseRua Bioscience Limited Interim Financial Statements - 31 December 2021
HY22 / financial reportcompany filing
FY22 / results announcementcompany filing
FY22 / results releaseRua Bioscience Ltd - FY22 Financial Statements
FY22 / financial reportRua Accelerates Export Strategy, Ceases Manufacturing
HY23 / commentaryAnnouncement - ASM Slides and Commentary Available
HY23 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.